In in connection with the closing of a public offering (the Offering”), the Company issued an aggregate of shares of common stock, including the shares issued in connection with the exercise of the underwriters’ overallotment option, at a public offering price of per share for gross proceeds of approximately The net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses, were approximately  

 

In the Company issued restricted shares of its common stock at a value of a share, or an aggregate value of approximately

 

In in connection with the closing of the Offering, the Company issued an aggregate of shares of common stock, including the shares issued in connection with the exercise of the underwriters’ overallotment option, at a public offering price of per share for gross proceeds of approximately The net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses, were approximately  

 

Through the ATM Facility, the Company offer and sell, from time-to-time, up to aggregate offering price of shares of its common stock. During the years ended and the Company sold shares for net proceeds of approximately and shares for net proceeds of approximately respectively. As of the company has sold an aggregate of shares of common stock under the ATM Facility for net proceeds of approximately As of the Company has sold shares of common stock under the ATM Facility for net proceeds of approximately

 

 In the Company issued restricted shares of its common stock at a value of a share, or an aggregate value of approximately

 

In in connection with the closing of the Offering, the Company issued an aggregate of shares of common stock, including the exercise of the underwriters’ overallotment option, at a public offering price of per share for gross proceeds of approximately The net proceeds to the Company, after the deduction of underwriting discounts, commissions and other offering expenses, were approximately

  

 

As of and outstanding warrants to purchase shares of common stock were as follows: 

 

														Number of
														Shares
														Outstanding
		Exercisable				Expiration				Exercise				Under
Issuance Date		for				Date				Price				Warrants
September 2014		Common Shares				September 23, 2019				$	4.24				86,831
October 2014		Common Shares				October 13, 2019				$	4.24				29,000
November 2014		Common Shares				November 12, 2019				$	4.24				12,500
February 2015		Common Shares				February 17, 2025				$	4.00				75,697
March 2015		Common Shares				March 26, 2025				$	2.72				1,454
May 2015		Common Shares				May 12, 2025				$	4.24				36,229
May 2015		Common Shares				May 17, 2020				$	4.24				21,585
December 2015		Common Shares				December 16, 2025				$	5.60				26,875
April 2016		Common Shares				April 1, 2026				$	6.08				25,000
May 2016		Common Shares				May 11, 2021				$	7.74				5,000
June 2016		Common Shares				June 20, 2026				$	4.98				100,402
May 2017		Common Shares				May 25, 2027				$	9.50				222,049
															642,622

 

In connection with the Loan Agreement, the Company issued a warrant to purchase a total of shares of common stock at an exercise price of per share. The Company determined the fair value of the warrant on the date of issuance to be The fair value along with legal fees totaling was recorded as debt issuance costs and was amortized to interest expense over the loan term. The debt issuance costs were presented in the consolidated balance sheet as a deduction from the carrying amount of the note payable. The outstanding indebtedness was repaid in from the proceeds of the new term loan in connection with the Loan Agreement and the remaining unamortized balance of debt issuance costs was recorded to interest expense. During the year ended the Company recorded of interest expense relating to the debt issuance costs.

  

In connection with the Loan Agreement, the Company issued warrants to purchase a total of shares of common stock at an exercise price of per share. The warrants have a contractual life of years and are exercisable immediately in whole or in part. The Company determined the fair value of the warrants on the date of issuance to be using the Black-Scholes option pricing model. Assumptions used were dividend yield of volatility of risk free interest rate of and a contractual life of years. The fair value of the warrants along with financing and legal fees totaling are recorded as debt issuance costs and presented in the consolidated balance sheets as a deduction from the carrying amount of the note payable. The debt issuance costs are amortized to interest expense over the loan term. During the years ended and the Company recorded and respectively, of interest expense relating to the debt issuance costs using the effective interest method. As of the unamortized debt discount was

 

shares, issuable pursuant to warrants issued in connection with a private offering on were issued in connection with the exercise of warrants during the years ended and respectively.

  

shares issuable pursuant to warrants have been cancelled during the year ended and

  

The stock-based compensation expense related to warrants issued was for the years ended and respectively.